Note 4 - Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Fair Value Measurements at September 30, 2018
			Quoted Prices in		Significant Other		Significant
			Active Markets for		Observable		Unobservable
	Balance at		Identical Assets		Inputs		Inputs
	September 30, 2018		(Level 1)		(Level 2)		(Level 3)
Assets:
Money market funds	$	145,515	$	145,515	$	-	$	-
Total assets	$	145,515	$	145,515	$	-	$	-
Liabilities:
Contingent consideration liability	$	10,900	$	-	$	-	$	10,900
Total liabilities	$	10,900	$	-	$	-	$	10,900

			Fair Value Measurements at December 31, 2017
			Quoted Prices in		Significant Other		Significant
			Active Markets for		Observable		Unobservable
	Balance at		Identical Assets		Inputs		Inputs
	December 31, 2017		(Level 1)		(Level 2)		(Level 3)
Assets:
Money market funds	$	87,231	$	87,231	$	-	$	-
Total assets	$	87,231	$	87,231	$	-	$	-
Liabilities:
Contingent consideration liability	$	16,800	$	-	$	-	$	16,800
Total liabilities	$	16,800	$	-	$	-	$	16,800

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Program	Consideration		Form of Payment at Progenics' Option
AZEDRA	$	8,000	Cash or Progenics common stock
1404		10,000	Cash or Progenics common stock
1095		5,000	Cash or Progenics common stock
	$	23,000

	Consideration		Form of Payment at Progenics' Option
$30 million	$	5,000	Cash or Progenics common stock
$60 million		5,000	Cash or Progenics common stock
$100 million		10,000	Cash or Progenics common stock
$250 million		20,000	Cash or Progenics common stock
$500 million		30,000	Cash or Progenics common stock
	$	70,000

Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]

	Fair Value at
	September 30,
	2018		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
AZEDRA commercialization	$	7,000	Probability adjusted discounted	Probability of success		90%
			cash flow model	Period of expected milestone achievement		2019
				Discount rate		10%
1095 commercialization		400	Probability adjusted discounted	Probability of success		16%
			cash flow model	Period of expected milestone achievement		2025
				Discount rate		10%
Net sales targets		3,500	Monte-Carlo simulation	Probability of success	16%	-	90%
				Discount rate		10%
Total	$	10,900

	Fair Value at
	December 31,
	2017		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
AZEDRA commercialization	$	5,500	Probability adjusted discounted	Probability of success		72%
			cash flow model	Period of expected milestone achievement		2018
				Discount rate		10%
1404 commercialization		4,500	Probability adjusted discounted	Probability of success		59%
			cash flow model	Period of expected milestone achievement		2020
				Discount rate		10%
1095 commercialization		400	Probability adjusted discounted	Probability of success		16%
			cash flow model	Period of expected milestone achievement		2025
				Discount rate		10%
Net sales targets		6,400	Monte-Carlo simulation	Probability of success	16%	-	72%
				Discount rate		10%
Total	$	16,800

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Liability - Contingent Consideration
	Fair Value Measurements Using
	Significant Unobservable Inputs
	(Level 3)
	Three Months Ended September 30,					Nine Months Ended September 30,
	2018			2017		2018			2017
Balance at beginning of period	$	18,900		$	16,800	$	16,800		$	14,200
Fair value change included in net loss		(8,000	)		700		(5,900	)		3,300
Balance at end of period	$	10,900		$	17,500	$	10,900		$	17,500
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	(8,000	)	$	700	$	(5,900	)	$	3,300